About Us
I N N O V A T I O N I N G L U C O S E M E A S U R E M E N T T E C H N O L O G Y SM
Early Innovations
TecMed, Inc is an intellectual property (IP) Wyoming Corporation with deep roots in New Mexico. Our story begins nearly two decades ago when CEO Alan Leszinske began to explore blood glucose and various blood glucose measurement technologies. As his knowledge grew, so did his understanding of the need for accurate, reliable, continuous and real-time blood glucose measurement technology in intensive care and critical care environments. Thus began the journey of TecMed which has culminated in technology that is more than 50% more accurate than our competitors and a company that works passionately to create technology that creates an opportunity for exceptional patient healthcare in the U.S. and abroad.
TecMed, Inc. © 2022 All Rights Reserved
TecMed has created, patented, and proven an intellectual property solutions portfolio - with a core optical measurement technology that is unparalleled in its accuracy and low cost of commercialization. No other company or technology has been able to match the accuracy, timeliness, frequency of measure, or cost savings potential that TecMed has achieved.
From the early days of inquiry, the research team at TecMed has had an unwavering interest in blood glucose measurement and was determined and focused on developing a safe, reliable measurement technology that could provide accurate, continuous, real-time blood glucose readings
Early attention was focused solely on a non-invasive consumer glucose meter for diabetics. However, focus later shifted to the automated perioperative/critical care blood glucose monitoring technology as it was the more complete and commercially viable technology.
Today TecMed, Inc. is a mature intellectual property company with ground-breaking – yet proven and patented, optical measurement technology. What began as a one-man science project has grown into a competitive and robust medical technology IP Company, with more than $76 million in capitalization. TecMed's advanced glucose measurement technology IP portfolio meets and surpasses the demands and requirements of present day government medical device mandates and is 50% more accurate than others.
Our History
Vision and Purpose
The vision we maintain at TecMed drives our purpose. Our intellectual property sets the groundwork to provide exceptional health care outcomes for individuals worldwide through advancements in blood glucose measurement technology. Secondly, our business model promotes the opportunity to generate exceptional profits for our shareholders, partners and investors through the creation, refinements and commercialization of IP directed toward innovative solutions in blood glucose measurement and management. These unserved and under-served markets represent many hundreds of millions of dollars annually in financial opportunity for our organization.
The vision we maintain at TecMed drives our purpose. Our intellectual property sets the groundwork to provide exceptional health care outcomes for individuals worldwide through advancements in blood glucose measurement technology. Secondly, our business model promotes the opportunity to generate exceptional profits for our shareholders, partners and investors through the creation, refinements and commercialization of IP directed toward innovative solutions in blood glucose measurement and management. These unserved and under-served markets represent many hundreds of millions of dollars annually in financial opportunity for our organization.
At TecMed, we aspire to the creation, refinement, and formation of partnering relationships for commercialization of intellectual property directed toward innovative blood glucose measurement and monitoring.
Our Mission and Purpose